Literature DB >> 7963575

Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors.

S Salvadori1, B Gansbacher, A M Pizzimenti, K S Zier.   

Abstract

There is considerable evidence to demonstrate that immune function is abnormal in tumor-bearing mice, perhaps accounting, at least in part, for progressive tumor growth. In an attempt to generate an antitumor response, we used retroviral vectors to express IL-2 cDNA in CMS5, a murine fibrosarcoma. Mice inoculated with unmodified tumor cells suffered progressive tumor growth, whereas tumors secreting IL-2 were rejected or grew slowly. Animals bearing unmodified but not IL-2-secreting tumors also were immunosuppressed. On the basis of these observations, we were interested in how IL-2 secretion by the tumor cells prevented the onset of hyporesponsiveness. To identify biochemical differences between T cells of mice with parental vs slowly growing IL-2-secreting tumors, we examined signal transduction after activation through the CD3/TCR complex. Protein tyrosine phosphorylation was altered and calcium flux was reduced in cells of mice with parental tumors compared with animals with slowly growing IL-2-secreting tumors. In addition, levels of protein for the tyrosine kinases p56lck and p59fyn, as well as the TCR-zeta-chain, were reduced. These differences in signal transduction were observed for T cells of mice with parental and IL-2-secreting tumors of the same size, demonstrating that differences in tumor size alone could not explain our findings. Thus, IL-2 secretion by tumors seems to be able to prevent immunosuppression by maintaining normal signal transduction in T cells, facilitating the generation of antitumor responses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

3.  A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods.

Authors:  A M Deakin; K Singh; J S Crowe; J H Ellis; A Dalgleish; R J Leicester; C J Finlayson; W F Miles; P F Life
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

Review 4.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

5.  Tumor Therapy Applying Membrane-bound Form of Cytokines.

Authors:  Young Sang Kim
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

6.  Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients.

Authors:  M Pang; Y Setoyama; K Tsuzaka; K Yoshimoto; K Amano; T Abe; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.

Authors:  S J Hollingsworth; D Darling; J Gäken; W Hirst; P Patel; M Kuiper; P Towner; S Humphreys; F Farzaneh; G J Mufti
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

8.  T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.

Authors:  D L Levey; P K Srivastava
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.